Abstract
We reduced EAE severity by using two anti-allergic drugs. A control group of mice received i.p. injections of PBS as vehicle while a further two groups were treated either with pyrilamine, a histamine receptor 1 antagonist or with CV6209, a platelet activating factor receptor antagonist. Our results showed that the blockade of the responses to both histamine and PAF leads together to a decline in clinical signs of EAE and significant changes in the serum IgG recognition of some healthy brain antigenic targets. We characterized two discriminant antigens: internexin neuronal intermediate filament protein, and malate dehydrogenase 1, which were able to clearly distinguish untreated mice from treated mice. Their role as potent targets in pathogenic and/or neuroprotective processes is discussed.
MeSH terms
-
Animals
-
Anti-Allergic Agents / pharmacology*
-
Antibodies, Anti-Idiotypic / blood
-
Antibodies, Anti-Idiotypic / immunology*
-
Central Nervous System / immunology
-
Electrophoresis
-
Encephalomyelitis, Autoimmune, Experimental / immunology*
-
Female
-
Histamine Antagonists / pharmacology
-
Histamine H1 Antagonists / pharmacology
-
Immunoblotting
-
Immunoglobulin G / immunology*
-
Intermediate Filament Proteins / immunology
-
Malate Dehydrogenase / immunology
-
Mice
-
Mice, Inbred Strains
-
Platelet Activating Factor / antagonists & inhibitors
-
Platelet Membrane Glycoproteins / antagonists & inhibitors
-
Proteomics
-
Pyridinium Compounds / pharmacology
-
Pyrilamine / pharmacology
-
Receptors, G-Protein-Coupled / antagonists & inhibitors
-
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Substances
-
Anti-Allergic Agents
-
Antibodies, Anti-Idiotypic
-
Histamine Antagonists
-
Histamine H1 Antagonists
-
Immunoglobulin G
-
Intermediate Filament Proteins
-
Platelet Activating Factor
-
Platelet Membrane Glycoproteins
-
Pyridinium Compounds
-
Receptors, G-Protein-Coupled
-
alpha-internexin
-
platelet activating factor receptor
-
CV 6209
-
Malate Dehydrogenase
-
Pyrilamine